Astel­las signs Asian li­cens­ing deal with Aquinox; Ar­a­vive touts ear­ly-stage PoC

→ Tokyo’s Astel­las Phar­ma has inked a li­cens­ing deal with Van­cou­ver’s Aquinox Phar­ma­ceu­ti­cal, snag­ging de­vel­op­ment and com­mer­cial­iza­tion rights for Aquinox’s lead drug can­di­date rosip­tor in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.